Results 181 to 190 of about 6,042 (221)

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

Gastroenterology, 2022
Walter Reinisch, Julian Panes, Chenglong Han   +2 more
exaly  

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelo Ruggiero, Fabrizio Martora
exaly  

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Expert Review of Clinical Immunology, 2021
Wolf-Henning Boehncke, Michael John Nissen   +1 more
exaly  

Etanercept/guselkumab

Reactions Weekly, 2023
openaire   +1 more source

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Lancet, The, 2020
Atul Deodhar, Mrcp, Philip S Helliwell, Wolf-Henning Boehncke   +2 more
exaly  

Apremilast/guselkumab

Reactions Weekly, 2022
openaire   +1 more source

Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease

Journal of Dermatological Treatment, 2021
Hannah Berman Ba, Natalie M Villa, V Y Shi   +2 more
exaly  

Guselkumab (Tremfya) for Ulcerative Colitis

The Medical Letter on Drugs and Therapeutics
The interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of
openaire   +2 more sources

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

Journal of Dermatological Treatment, 2022
Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli   +2 more
exaly  

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Lancet, The, 2018
Atul Deodhar, Mrcp, Alice B Gottlieb, Wolf-Henning Boehncke   +2 more
exaly